Publications
Research at the Leibniz Institute for Immunology focuses on the development of pioneering immune-cell therapies targeting cancer, autoimmune diseases, and chronic inflammation. While developments in this field are highly relevant within the medical community, they are also of great interest to the wider general public. The LIT has a comprehensive archive of international articles, publications, lectures, and online resources aimed at a variety of audiences. So, whoever you are, if you do not find what you are looking for, please do not hesitate to contact us.
Gonzalez-Velasco O, Simon M, Yilmaz R, Parlato R, Weishaupt J, Imbusch CD, Brors B. Identifying similar populations across independent single cell studies without data integration. NAR Genom Bioinform. 2025 Jun. 7:lqaf042. doi:10.1093/nargab/lqaf042. PMID: 40276039
Habenicht KM, Wanzek J, Bootz A, Schafer S, Vollmer L, Hiergeist A, Fante M, Hasenbank J, Schneider A, Vasova I, Spoerl S, Brandt A, Rehli M, Hoffmann P, Wirtz S, Kotorri J, Gerlach RG, Gessner A, Mackensen A, Winkler J, Wolff D, Winkler TH. Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD. Blood. 2025 Jun 26. 145:3178-3188. doi:10.1182/blood.2024027301. PMID: 40324063
Hindriks E, Bergmann W, Ruiz AM, De Maria R, Zandvliet M, Sijts A, Broere F. Cancer-testis antigen expression in canine melanoma and healthy tissues. Vet Immunol Immunopathol. 2025 Jun. 284:110946. doi:10.1016/j.vetimm.2025.110946. PMID: 40359694
Harrer DC, Schlierkamp-Voosen T, Barden M, Pan H, Xydia M, Herr W, Dorrie J, Schaft N, Abken H. Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion. Cells. 2025 Jun 14. 14doi:10.3390/cells14120901. PMID: 40558528
Scheller L, Elia M, Bonati L, Kang C, Gainza P, Garodia Y, Deshpande P, Schmidt J, Enbar T, Georgeon S, Tang L, Correia BE. Humanized Caffeine-Inducible Systems for Controlling Cellular Functions. BioRxiv. 2025 doi:10.1101/2025.06.13.659463.
Holzinger A, Weber F, Abken H. The risk of reactivity against healthy tissues: Novel CARs demand testing for overlooked binding properties. Mol Ther. 2025 Jun 4. 33:2328-2329. doi:10.1016/j.ymthe.2024.12.035. PMID: 39818204
Flamann CS, Shaikh H, Matos C, Kreutz M, Ali H, Kern MA, Buttner-Herold M, Jacobs B, Volkl S, Lischer C, Kellner C, Berges J, Bitterer K, Saul D, Goel M, Link-Rachner C, Zernecke A, Weber DA, Mougiakakos D, Mackensen A, Beilhack A, Bruns H. Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT. Blood. 2025 May 7. doi:10.1182/blood.2023023056. PMID: 40332470
Brummer C, Singer K, Renner K, Bruss C, Hellerbrand C, Dorn C, Reichelt-Wurm S, Gronwald W, Pukrop T, Herr W, Banas M, Kreutz M. The spleen-liver axis supports obesity-induced systemic and fatty liver inflammation via MDSC and NKT cell enrichment. Mol Cell Endocrinol. 2025 May 1. 601:112518. doi:10.1016/j.mce.2025.112518. PMID: 40054835
Guetter S, Konig C, Koerkel-Qu H, Markiewicz A, Scheitler S, Katzer M, Berneburg M, Renner P, Cucuruz B, Guttenberger L, Naimer V, Weidele K, Treitschke S, Werno C, Jaser H, Bargmann T, Braun A, Weber F, Evert K, Rochwarger A, Schurch CM, Limm K, Oefner PJ, Rachel R, Baumann F et al. MCSP(+) metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization. Nat Cancer. 2025 May 16. doi:10.1038/s43018-025-00963-w. PMID: 40379833